These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 22072801

  • 1. The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
    Hu-Lowe D, Brega N, Patyna S.
    Mol Cancer Ther; 2011 Nov; 10(11):2015. PubMed ID: 22072801
    [No Abstract] [Full Text] [Related]

  • 2. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
    Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.
    Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
    [Abstract] [Full Text] [Related]

  • 3. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
    Christensen JG.
    Ann Oncol; 2007 Sep; 18 Suppl 10():x3-10. PubMed ID: 17761721
    [Abstract] [Full Text] [Related]

  • 4. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

  • 5. Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?
    Di Lorenzo L.
    J Clin Oncol; 2007 Jul 01; 25(19):2858-9; author reply 2859-61. PubMed ID: 17602094
    [No Abstract] [Full Text] [Related]

  • 6. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Zhu AX.
    Expert Rev Anticancer Ther; 2008 Apr 01; 8(4):499-505. PubMed ID: 18402516
    [No Abstract] [Full Text] [Related]

  • 7. Canertinib pfizer.
    Galmarini CM.
    IDrugs; 2004 Jan 01; 7(1):58-63. PubMed ID: 14730468
    [Abstract] [Full Text] [Related]

  • 8. Sunitinib: from rational design to clinical efficacy.
    Chow LQ, Eckhardt SG.
    J Clin Oncol; 2007 Mar 01; 25(7):884-96. PubMed ID: 17327610
    [Abstract] [Full Text] [Related]

  • 9. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.
    Mol Cancer Ther; 2006 May 01; 5(5):1280-9. PubMed ID: 16731761
    [Abstract] [Full Text] [Related]

  • 10. Targeting receptor tyrosine kinases in solid tumors.
    Zhang J, Hochwald SN.
    Surg Oncol Clin N Am; 2013 Oct 01; 22(4):685-703. PubMed ID: 24012395
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
    Zhou A, Zhang W, Chang C, Chen X, Zhong D, Qin Q, Lou D, Jiang H, Wang J.
    Cancer Chemother Pharmacol; 2013 Nov 01; 72(5):1043-53. PubMed ID: 24043137
    [Abstract] [Full Text] [Related]

  • 12. Multitarget tyrosine kinase inhibition: [and the winner is...].
    Verweij J, de Jonge M.
    J Clin Oncol; 2007 Jun 10; 25(17):2340-2. PubMed ID: 17557945
    [No Abstract] [Full Text] [Related]

  • 13. Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
    Howard SA, Rosenthal MH, Jagannathan JP, Krajewski KM, Shinagare AB, Ramaiya NH, Tirumani SH.
    AJR Am J Roentgenol; 2015 May 10; 204(5):919-32. PubMed ID: 25905926
    [Abstract] [Full Text] [Related]

  • 14. Protein kinase inhibitors: novel tools in cancer therapy.
    Marmé D.
    Urologe A; 2004 Sep 10; 43 Suppl 3():S148. PubMed ID: 15148578
    [No Abstract] [Full Text] [Related]

  • 15. Cancer and kinases: reports from the front line.
    Burley SK.
    Genome Biol; 2006 Sep 10; 7(4):314. PubMed ID: 16677415
    [Abstract] [Full Text] [Related]

  • 16. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    Papaetis GS, Syrigos KN.
    BioDrugs; 2009 Sep 10; 23(6):377-89. PubMed ID: 19894779
    [Abstract] [Full Text] [Related]

  • 17. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF, Blum HE, Geissler M.
    Dtsch Med Wochenschr; 2005 Jun 10; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract] [Full Text] [Related]

  • 18. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K, Hanahan D.
    J Clin Oncol; 2005 Feb 10; 23(5):939-52. PubMed ID: 15557593
    [Abstract] [Full Text] [Related]

  • 19. Endothelial survival factors as targets for antineoplastic therapy.
    Reinmuth N, Stoeltzing O, Liu W, Ahmad SA, Jung YD, Fan F, Parikh A, Ellis LM.
    Cancer J; 2001 Feb 10; 7 Suppl 3():S109-19. PubMed ID: 11779081
    [Abstract] [Full Text] [Related]

  • 20. Targeted therapy and new anticancer drugs in advanced disease.
    Silva S, Danson S.
    Thorac Surg Clin; 2013 Aug 10; 23(3):411-9. PubMed ID: 23931023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.